Rocket Pharmaceuticals (RCKT) Projected to Post Quarterly Earnings on Thursday

Key Points

• Earnings due May 14 (before market): Rocket is expected to report Q1 2026 results with analysts forecasting ($0.41) EPS and about $4.47 million in revenue, and a company call is scheduled for May 11 at 4:00 PM ET.
• Shares trade near $3.86 with a market cap of ~$421M; Wall Street sentiment is mixed—MarketBeat shows a consensus "Hold" rating and an average price target of $13.86, though analyst ratings range from strong-buy to sell, and the prior quarter slightly topped estimates.
• Insiders (including the CEO and General Counsel) sold roughly 12k shares each in February, insiders still own about 21.3% of the stock while institutional/hedge fund ownership is reported to be very high (~98%).

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $4.4670 million for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.04. During the same quarter in the previous year, the company earned ($0.62) earnings per share. On average, analysts expect Rocket Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rocket Pharmaceuticals Stock Up 9.0%

Shares of NASDAQ RCKT opened at $3.86 on Thursday. The company has a quick ratio of 6.38, a current ratio of 6.38 and a debt-to-equity ratio of 0.07. Rocket Pharmaceuticals has a 52 week low of $2.19 and a 52 week high of $7.39. The firm's fifty day moving average is $4.10 and its 200 day moving average is $3.69. The company has a market cap of $421.20 million, a price-to-earnings ratio of -1.92 and a beta of 0.52.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on RCKT shares. Lifesci Capital raised shares of Rocket Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, February 26th. Chardan Capital reaffirmed a "buy" rating and issued a $11.00 target price on shares of Rocket Pharmaceuticals in a research note on Friday, March 27th. The Goldman Sachs Group lifted their target price on shares of Rocket Pharmaceuticals to $3.00 and gave the stock a "sell" rating in a research note on Monday, March 2nd. Cantor Fitzgerald lifted their target price on shares of Rocket Pharmaceuticals from $8.00 to $10.00 and gave the stock an "overweight" rating in a research note on Friday, February 27th. Finally, Bank of America lifted their target price on shares of Rocket Pharmaceuticals from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, Rocket Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $13.86.

Insiders Place Their Bets

In other Rocket Pharmaceuticals news, General Counsel Martin Wilson sold 12,253 shares of the business's stock in a transaction on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,557.43. Following the transaction, the general counsel directly owned 683,376 shares of the company's stock, valued at approximately $2,261,974.56. The trade was a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Gaurav Shah sold 12,279 shares of the business's stock in a transaction on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,643.49. Following the transaction, the chief executive officer directly owned 1,052,045 shares in the company, valued at approximately $3,482,268.95. The trade was a 1.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 29,415 shares of company stock worth $97,398. Insiders own 21.30% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC purchased a new position in Rocket Pharmaceuticals during the 4th quarter valued at $49,000. Corient Private Wealth LLC purchased a new stake in shares of Rocket Pharmaceuticals in the 4th quarter worth about $98,000. Invesco Ltd. grew its position in shares of Rocket Pharmaceuticals by 36.9% in the 4th quarter. Invesco Ltd. now owns 304,437 shares of the biotechnology company's stock worth $1,069,000 after buying an additional 81,984 shares during the period. Virtus Investment Advisers LLC grew its position in shares of Rocket Pharmaceuticals by 111.7% in the 4th quarter. Virtus Investment Advisers LLC now owns 78,474 shares of the biotechnology company's stock worth $275,000 after buying an additional 41,410 shares during the period. Finally, Opaleye Management Inc. purchased a new stake in shares of Rocket Pharmaceuticals in the 4th quarter worth about $3,352,000. 98.39% of the stock is owned by hedge funds and other institutional investors.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company's pipeline comprises multiple product candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.